Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Epizyme Inc (NASDAQ:EPZM)

12.70
Delayed Data
As of Dec 15
 0.00 / 0.00%
Today’s Change
9.30
Today|||52-Week Range
20.45
+4.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$879.9M

Company Description

Epizyme, Inc. operates as a clinical stage biopharmaceutical company. It discovers, develops and plans to commercialize novel epigenetic therapies for patients with cancer and other diseases. The company engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases. Its products include Tazemetostat, which is used for the treatment of multiple types of hematological malignancies and genetically defined solid tumors; and Pinometostat, which is used for treatment of patients with MLL-r, a genetically defined acute leukemia. Epizyme was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA.

Contact Information

Epizyme, Inc.
400 Technology Square
Cambridge Massachusetts 02139
P:(617) 229-5872
Investor Relations:
(617) 401-0721

Employees

Shareholders

Mutual fund holders42.85%
Individual stakeholders31.27%
Other institutional30.83%

Top Executives

Robert B. BazemorePresident, CEO, Secretary & Director
Matthew E. RosChief Operating Officer
Suzanne FlemingTreasurer, Chief Accounting Officer & SVP-Finance
Tai-Ching HoChief Medical Officer & Executive Vice President
Michael BorettiVice President-Business Development